281 related articles for article (PubMed ID: 25686543)
1. Intermediate-Term Risk of Prostate Cancer is Directly Related to Baseline Prostate Specific Antigen: Implications for Reducing the Burden of Prostate Specific Antigen Screening.
Gelfond J; Choate K; Ankerst DP; Hernandez J; Leach RJ; Thompson IM
J Urol; 2015 Jul; 194(1):46-51. PubMed ID: 25686543
[TBL] [Abstract][Full Text] [Related]
2. Risk of prostate cancer for young men with a prostate specific antigen less than their age specific median.
Loeb S; Nadler RB; Roehl KA; Antenor JA; Catalona WJ
J Urol; 2007 May; 177(5):1745-8. PubMed ID: 17437803
[TBL] [Abstract][Full Text] [Related]
3. Cumulative risk of developing prostate cancer in men with low (≤ 2.0 ng/mL) prostate-specific antigen levels: a population-based screening cohort study in Japan.
Sawada K; Kitagawa Y; Ito K; Takeda Y; Mizokami A; Namiki M
Int J Urol; 2014 Jun; 21(6):560-5. PubMed ID: 24372775
[TBL] [Abstract][Full Text] [Related]
4. Prostate specific antigen changes as related to the initial prostate specific antigen: data from the prostate, lung, colorectal and ovarian cancer screening trial.
Crawford ED; Pinsky PF; Chia D; Kramer BS; Fagerstrom RM; Andriole G; Reding D; Gelmann EP; Levin DL; Gohagan JK
J Urol; 2006 Apr; 175(4):1286-90; discussion 1290. PubMed ID: 16515981
[TBL] [Abstract][Full Text] [Related]
5. Prostate cancer risk assessment program: a 10-year update of cancer detection.
Giri VN; Beebe-Dimmer J; Buyyounouski M; Konski A; Feigenberg SJ; Uzzo RG; Hanks G; Godwin AK; Chen DY; Gordon R; Cescon T; Raysor S; Watkins-Bruner D
J Urol; 2007 Nov; 178(5):1920-4; discussion 1924. PubMed ID: 17868726
[TBL] [Abstract][Full Text] [Related]
6. Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old.
Loeb S; Roehl KA; Antenor JA; Catalona WJ; Suarez BK; Nadler RB
Urology; 2006 Feb; 67(2):316-20. PubMed ID: 16442597
[TBL] [Abstract][Full Text] [Related]
7. Relationship between initial prostate specific antigen level and subsequent prostate cancer detection in a longitudinal screening study.
Antenor JA; Han M; Roehl KA; Nadler RB; Catalona WJ
J Urol; 2004 Jul; 172(1):90-3. PubMed ID: 15201744
[TBL] [Abstract][Full Text] [Related]
8. Prostate specific antigen velocity in men with total prostate specific antigen less than 4 ng/ml.
Loeb S; Roehl KA; Nadler RB; Yu X; Catalona WJ
J Urol; 2007 Dec; 178(6):2348-52; discussion 2352-3. PubMed ID: 17936844
[TBL] [Abstract][Full Text] [Related]
9. Prediagnosis prostate specific antigen velocity is associated with risk of prostate cancer progression following brachytherapy and external beam radiation therapy.
Eggener SE; Roehl KA; Yossepowitch O; Catalona WJ
J Urol; 2006 Oct; 176(4 Pt 1):1399-403. PubMed ID: 16952643
[TBL] [Abstract][Full Text] [Related]
10. Histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostate-specific antigen (PSA) concentration in the Finnish prostate cancer screening trial.
Yli-Hemminki TH; Laurila M; Auvinen A; Määttänen L; Huhtala H; Tammela TL; Kujala PM
BJU Int; 2013 Oct; 112(6):735-41. PubMed ID: 23746332
[TBL] [Abstract][Full Text] [Related]
11. Relationship among initial serum prostate specific antigen, prostate specific antigen progression and prostate cancer detection at repeat screening visits.
Candas B; Labrie F; Gomez JL; Cusan L; Chevrette E; Lévesque J; Brousseau G
J Urol; 2006 Feb; 175(2):510-6; discussion 516-7. PubMed ID: 16406983
[TBL] [Abstract][Full Text] [Related]
12. Disease-specific survival of men with prostate cancer detected during the screening interval: results of the European randomized study of screening for prostate cancer-Rotterdam after 11 years of follow-up.
Zhu X; van Leeuwen PJ; Bul M; Otto SJ; de Koning HJ; Bangma CH; Schröder FH; Roobol MJ
Eur Urol; 2011 Aug; 60(2):330-6. PubMed ID: 21601352
[TBL] [Abstract][Full Text] [Related]
13. Defining increased future risk for prostate cancer: evidence from a population based screening cohort.
Schröder FH; Roobol MJ; Andriole GL; Fleshner N
J Urol; 2009 Jan; 181(1):69-74; discussion 74. PubMed ID: 19012915
[TBL] [Abstract][Full Text] [Related]
14. Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam).
Roobol MJ; Roobol DW; Schröder FH
Urology; 2005 Feb; 65(2):343-6. PubMed ID: 15708050
[TBL] [Abstract][Full Text] [Related]
15. Age adjusted prostate specific antigen and prostate specific antigen velocity cut points in prostate cancer screening.
Moul JW; Sun L; Hotaling JM; Fitzsimons NJ; Polascik TJ; Robertson CN; Dahm P; Anscher MS; Mouraviev V; Pappas PA; Albala DM
J Urol; 2007 Feb; 177(2):499-503; discussion 503-4. PubMed ID: 17222618
[TBL] [Abstract][Full Text] [Related]
16. A framework for the identification of men at increased risk for prostate cancer.
Roobol MJ; Schröder FH; Crawford ED; Freedland SJ; Sartor AO; Fleshner N; Andriole GL
J Urol; 2009 Nov; 182(5):2112-20. PubMed ID: 19758625
[TBL] [Abstract][Full Text] [Related]
17. Prostate specific antigen velocity threshold for predicting prostate cancer in young men.
Loeb S; Roehl KA; Catalona WJ; Nadler RB
J Urol; 2007 Mar; 177(3):899-902. PubMed ID: 17296371
[TBL] [Abstract][Full Text] [Related]
18. Impact of PSA levels on second-round screening for the development of prostate cancer in men with low baseline PSA levels (≤2.0 mg/ml).
Kitagawa Y; Sawada K; Urata S; Izumi K; Ueno S; Kadono Y; Konaka H; Mizokami A; Namiki M
Anticancer Res; 2014 Nov; 34(11):6739-46. PubMed ID: 25368284
[TBL] [Abstract][Full Text] [Related]
19. National trends in prostate cancer screening among older American men with limited 9-year life expectancies: evidence of an increased need for shared decision making.
Drazer MW; Prasad SM; Huo D; Schonberg MA; Dale W; Szmulewitz RZ; Eggener SE
Cancer; 2014 May; 120(10):1491-8. PubMed ID: 24523016
[TBL] [Abstract][Full Text] [Related]
20. A model of prostate-specific antigen screening outcomes for low- to high-risk men: information to support informed choices.
Howard K; Barratt A; Mann GJ; Patel MI
Arch Intern Med; 2009 Sep; 169(17):1603-10. PubMed ID: 19786680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]